Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study

被引:195
作者
Pietersen, Elize [1 ,2 ]
Ignatius, Elisa [3 ]
Streicher, Elizabeth M. [4 ,5 ,6 ]
Mastrapa, Barbara [7 ]
Padanilam, Xavier [8 ]
Pooran, Anil [1 ,2 ]
Badri, Motasim [9 ,10 ]
Lesosky, Maia [9 ]
van Helden, Paul [4 ,5 ,6 ]
Sirgel, Frederick A. [4 ,5 ,6 ]
Warren, Robin [4 ,5 ,6 ]
Dheda, Keertan [1 ,2 ]
机构
[1] Univ Cape Town, Div Pulmonol, Lung Infect & Immun Unit, ZA-7925 Cape Town, South Africa
[2] Univ Cape Town, Dept Med, Lung Inst, ZA-7925 Cape Town, South Africa
[3] Emory Univ, Sch Med, Dept Internal Med, Atlanta, GA USA
[4] Univ Stellenbosch, Dept Sci & Technol, ZA-7505 Tygerberg, South Africa
[5] Univ Stellenbosch, Natl Res Fdn, Ctr Excellence Biomed TB Res, ZA-7505 Tygerberg, South Africa
[6] Univ Stellenbosch, MRC, Ctr Mol & Cellular Biol, Div Mol Biol & Human Genet,Fac Med & Hlth Sci, ZA-7505 Tygerberg, South Africa
[7] Gordonia Prov Hosp, Upington, South Africa
[8] Sizwe Trop Dis Hosp, Johannesburg, South Africa
[9] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa
[10] King Saud Bin Abdulaziz Univ Hlth Sci, Coll Sci & Hlth Profess, Riyadh, Saudi Arabia
基金
英国医学研究理事会; 新加坡国家研究基金会;
关键词
MYCOBACTERIUM-TUBERCULOSIS; EMERGENCE; HIV; EPIDEMIOLOGY; CLOFAZIMINE; MUTATIONS; TMC207;
D O I
10.1016/S0140-6736(13)62675-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Long-term treatment-related outcomes in patients with extensively drug-resistant (XDR) tuberculosis are unknown. We followed up a cohort of patients to address knowledge gaps. Methods Between March, 2008, and August, 2012, we prospectively followed up a cohort of 107 patients from three provinces in South Africa, who had been diagnosed with XDR tuberculosis between August 2002, and February, 2008. Available isolates from 56 patients were genotyped to establish strain type and used for extended susceptibility testing. Findings All patients were treated empirically as inpatients with a median of eight drugs (IQR six to ten). 44 patients (41%) had HIV. 36 (64%) of 56 isolates were resistant to at least eight drugs, and resistance to an increasing number of drugs was associated with the Beijing genotype (p=0.01). After 24 months of follow-up, 17 patients (16%) had a favourable outcome (ie, treatment cure or completion), 49 (46%) had died, seven (7%) had defaulted (interruption of treatment for at least 2 consecutive months), and 25 (23%) had failed treatment. At 60 months, 12 patients (11%) had a favourable outcome, 78 (73%) had died, four (4%) had defaulted, and 11 (10%) had failed treatment. 45 patients were discharged from hospital, of whom 26 (58%) had achieved sputum culture conversion and 19 (42%) had failed treatment. Median survival of patients who had failed treatment from time of discharge was 19.84 months (IQR 4.16-26.04). Clustering of cases and transmission within families containing a patient who had failed treatment and been discharged were shown with genotypic methods. Net sputum culture conversion occurred in 22 patients (21%) and median time to net culture conversion was 8.7 months (IQR 5.6-26.4). Independent predictors of probability of net culture conversion were no history of multidrug-resistant tuberculosis (p=0.0007) and use of clofazamine (p=0.0069). Independent overall predictors of survival were net culture conversion (p<0.0001) and treatment with clofazamine (p=0.021). Antiretroviral therapy was also a predictor of survival in patients with HIV (p=0.003). Interpretation In South Africa, long-term outcomes in patients with XDR tuberculosis are poor, irrespective of HIV status. Because appropriate long-stay or palliative care facilities are scarce, substantial numbers of patients with XDR tuberculosis who have failed treatment and have positive sputum cultures are being discharged from hospital and are likely to transmit disease into the wider community. Testing of new combined regimens is needed urgently and policy makers should implement interventions to minimise disease spread by patients who fail treatment.
引用
收藏
页码:1230 / 1239
页数:10
相关论文
共 36 条
[1]  
[Anonymous], 2010, Multidrug and extensively drug-resistant TB(M/XDR-TB): 2010 Global Report on Surveillance and Response
[2]  
Barrera L., 2008, Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs
[3]   The re-emergence of tuberculosis: what have we learnt from molecular epidemiology? [J].
Borgdorff, M. W. d ;
van Soolingen, D. .
CLINICAL MICROBIOLOGY AND INFECTION, 2013, 19 (10) :889-901
[4]   Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection [J].
Chaisson, RE ;
Keiser, P ;
Pierce, M ;
Fessel, WJ ;
Ruskin, J ;
Lahart, C ;
Benson, CA ;
Meek, K ;
Siepman, N ;
Craft, JC .
AIDS, 1997, 11 (03) :311-317
[5]   The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? [J].
Dheda, Keertan ;
Migliori, Giovanni B. .
LANCET, 2012, 379 (9817) :773-775
[6]   Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study [J].
Dheda, Keertan ;
Shean, Karen ;
Zumla, Alimuddin ;
Badri, Motasim ;
Streicher, Elizabeth M. ;
Page-Shipp, Liesl ;
Willcox, Paul ;
John, Melanie-Anne ;
Reubenson, Gary ;
Govindasamy, Darshini ;
Wong, Michelle ;
Padanilam, Xavier ;
Dziwiecki, Alicia ;
van Helden, Paul D. ;
Siwendu, Sweetness ;
Jarand, Julie ;
Menezes, Colin N. ;
Burns, Avril ;
Victor, Thomas ;
Warren, Robin ;
Grobusch, Martin P. ;
van der Walt, Martie ;
Kvasnovsky, Charlotte .
LANCET, 2010, 375 (9728) :1798-1807
[7]   Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance [J].
Diacon, A. H. ;
Donald, P. R. ;
Pym, A. ;
Grobusch, M. ;
Patientia, R. F. ;
Mahanyele, R. ;
Bantubani, N. ;
Narasimooloo, R. ;
De Marez, T. ;
van Heeswijk, R. ;
Lounis, N. ;
Meyvisch, P. ;
Andries, K. ;
McNeeley, D. F. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (06) :3271-3276
[8]   The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis [J].
Diacon, Andreas H. ;
Pym, Alexander ;
Grobusch, Martin ;
Patientia, Ramonde ;
Rustomjee, Roxana ;
Page-Shipp, Liesl ;
Pistorius, Christoffel ;
Krause, Rene ;
Bogoshi, Mampedi ;
Churchyard, Gavin ;
Venter, Amour ;
Allen, Jenny ;
Palomino, Juan Carlos ;
De Marez, Tine ;
van Heeswijk, Rolf P. G. ;
Lounis, Nacer ;
Meyvisch, Paul ;
Verbeeck, Johan ;
Parys, Wim ;
de Beule, Karel ;
Andries, Koen ;
Mc Neeley, David F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (23) :2397-2405
[9]   Systematic review of clofazimine for the treatment of drug-resistant tuberculosis [J].
Gopal, M. ;
Padayatchi, N. ;
Metcalfe, J. Z. ;
O'Donnell, M. R. .
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2013, 17 (08) :1001-1007
[10]   Treatment Outcomes among Patients with Extensively Drug-Resistant Tuberculosis: Systematic Review and Meta-Analysis [J].
Jacobson, Karen R. ;
Tierney, Dylan B. ;
Jeon, Christie Y. ;
Mitnick, Carole D. ;
Murray, Megan B. .
CLINICAL INFECTIOUS DISEASES, 2010, 51 (01) :6-14